TIQ-A has been used as a PAPR-1 inhibitor to study eosinophilic infiltration into the airways of OVA-challenged mice1. It has also been used to study its role in the regression of atherosclerotic plaques in high-fat diet-fed ApoE(-/-) mice2.
Ações bioquímicas/fisiológicas
TIQ-A is a potent inhibitor of PARP, anti-apoptotic.
The Journal of pharmacology and experimental therapeutics, 329(1), 150-158 (2009-01-07)
We recently showed that poly(ADP-ribose) polymerase (PARP) is activated within atherosclerotic plaques in an animal model of atherosclerosis. Pharmacological inhibition of PARP or reduced expression in heterozygous animals interferes with atherogenesis and may promote factors of plaque stability, possibly reflecting
Journal of immunology (Baltimore, Md. : 1950), 177(9), 6489-6496 (2006-10-24)
We recently used a murine model of allergic airway inflammation to show that poly(ADP-ribose) polymerase-1 (PARP-1) plays an important role in the pathogenesis of asthma-related lung inflammation. In this study, we show that PARP-1 inhibition, by a novel inhibitor (TIQ-A)
Questions
Reviews
★★★★★ No rating value
Active Filters
Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.
